877264-77-2

Usage

Uses

Used in Pharmaceutical Research and Development:
1-BOC-6-BROMO-INDAZOLE is used as a building block for the synthesis of biologically active molecules, contributing to the development of new pharmaceuticals. Its presence of a BOC group and bromine substituent allows for the creation of a wide range of chemical compounds with potential therapeutic applications.
Used in Organic Synthesis:
As a synthetic intermediate, 1-BOC-6-BROMO-INDAZOLE is employed in the preparation of diverse chemical compounds. The BOC group serves a protective role, enabling the synthesis of complex molecules with specific functional groups that can be selectively deprotected when needed, facilitating the creation of intricate chemical structures for various applications in the chemical and pharmaceutical industries.

Upstream product

• 79762-54-2 6-bromo-1H-indazole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 890839-29-9 1,1-dimethylethyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole-1-carboxylate 
• 1426095-02-4 N-{[(3S)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indazol-6-yl)-N-methylbenzamide 
• 1426095-23-9 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-N-ethyl-4-(1H-indazyl)benzamide 
• 1426095-27-3 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indazol-6-yl)-N-(1-methylethyl)benzamide 
• 1426095-38-6 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indazol-6-yl)-N-(phenylmethyl)benzamide 
• 1301189-02-5 4-(1H-indazol-6-yl)benzaldehyde 

Relevant academic research and scientific papers

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to carboxamides and reverse carboxamides according to Formula (I) and the use of carboxamides and reverse carboxamides for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of carboxamides and reverse carboxamides in the treatment of cancer.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of imidazole, triazole, and tetrazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of imidazoles, triazoles, and tetrazoles in the treatment of cancer.

BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of benzimidazoles in the treatment of cancer.

AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of azabenzimidazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of azabenzimidazoles in the treatment of cancer.

1H-PYRROLO[2,3-B]PYRIDINES

Derivatives of pyrrolo[2,3-b]pyridine which are useful as SGK-1 kinase inhibitors are described herein. The invention described herein also describes pharmaceutical compositions containing derivatives of pyrrolo[2,3-b]pyridine and methods of using pyrrolo[2,3-b]pyridine derivatives and pharmaceutical compositions thereof in the treatment of diseases mediated by SGK-1.